



MAYNE PHARMA ANNOUNCES CHANGE OF AUDITOR

30 November 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma or the Company) announces that, following shareholder approval obtained at the Annual General Meeting held today, BDO Audit Pty Ltd (BDO) has been appointed as the auditor of the Company with effect from today, 30 November 2023.

The appointment of BDO follows receipt of resignation from Ernst & Young by the Company and the Australian Securities and Investments Commission's consent to the resignation in accordance with section 329(5) of the *Corporations Act 2001* (Cth).

The reason for the change in auditor was to give effect to the result of a competitive audit tender process conducted during 2023.

For further information contact:

Australia:

Craig Haskins

+61 421 029 843

ir@maynepharma.com

US:

Lisa M. Wilson

+1 917-543-9932

ir@maynepharma.com

Authorised for release to the ASX by the Board

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia